COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03042819
Recruitment Status : Active, not recruiting
First Posted : February 3, 2017
Last Update Posted : September 25, 2020
Karyopharm Therapeutics Inc
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:

This is a phase 1b study of investigational drug selinexor in combination with doxorubicin in patients with locally advanced or metastatic soft tissue sarcoma. The purpose of this study is to determine how safe and tolerable the combination is, as well as the best dose of the study drugs in this patient population.

Selinexor (also called KPT-330), works by trapping "tumor suppressor proteins" within the cell and thus causing the cancer cells to die or stop growing.

Condition or disease Intervention/treatment Phase
Soft Tissue Sarcoma Drug: Selinexor Drug: Doxorubicin Phase 1

Detailed Description:

This is a phase 1b study of investigational drug selinexor in combination with doxorubicin in patients with locally advanced or metastatic soft tissue sarcoma.

Patients will be screened for eligibility within 28 days of the start of the study drugs. In addition to standard tests and procedures, research tumor tissue (archival or fresh biopsy) will be collected for collection for pharmacodynamics. Participants will also be asked if they agree to optional biopsies at 6 cycles if their cancer is responding and at disease progression.

Eligible participants will then receive the study drugs in 21 day cycles. Selinexor will be given by mouth and doxorubicin will be given by vein, once a week, for 6 cycles.

Participants will be restaged every 2 cycles. If participants respond to treatment after 6 cycles, they may be able to continue the selinexor alone as a maintenance treatment until progression or unacceptable toxicity.

While receiving the study drug, many of the screening tests will be repeated. Additional tests and procedures include blood sample collection for pharmacokinetics and pharmacodynamics.

When participants stop the study drug permanently for any reason, an end of treatment visit, 28-day follow-up, and long term follow up every 90 days will occur.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Trial of Selinexor Plus Doxorubicin in Advanced Soft Tissue Sarcomas (STS)
Actual Study Start Date : May 16, 2017
Actual Primary Completion Date : November 30, 2019
Estimated Study Completion Date : November 15, 2021

Arm Intervention/treatment
Experimental: Selinexor plus Doxorubicin

Selinexor will be given by mouth (orally) once a week:

Dose Level -1 = 40 mg Dose Level 1 (Starting Dose) = 60 mg Dose Level 2 = 80 mg

Doxorubicin will be given by vein (intravenously) at a dose of 75 mg/m2 once every 3 weeks.

Drug: Selinexor
Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumor suppressor proteins (TSPs).

Drug: Doxorubicin
Doxorubicin is currently approved for various cancers. Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.

Primary Outcome Measures :
  1. To evaluate the Incidence of Treatment-Emergent Adverse Events, graded and categorized according to the CTCAE v4.0. [ Time Frame: 3 years ]
    All adverse events will be tabulated and summarized by major organ category, grade, anticipation, and drug attribution. SAE specific incidence and exact 95% confidence interval will be provided where appropriate.

  2. To determine the recommended phase II dose (RP2D) of Selinexor in combination with doxorubicin [ Time Frame: 3 years ]
    The RP2D will be determined according to interim mTPI monitoring algorithm (Figure 5.1) using the dose determining set.

Secondary Outcome Measures :
  1. Rate of Grade 3 Toxicities [ Time Frame: 3 years ]
  2. Response Rate [ Time Frame: 3 years ]
  3. Progression-free Survival Rate [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent
  • Patient must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
  • Age ≥ 18 years.
  • Patients must have histologically confirmed locally advanced/unresectable or metastatic soft tissue sarcoma.
  • Patients must have not received prior doxorubicin.
  • Patient must show evidence of progressive disease on study entry or newly diagnosed patients with de novo metastatic measurable disease
  • Patient must have measureable disease as defined by RECIST 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Adequate hematopoietic function
  • Adequate hepatic function:
  • Adequate renal function
  • Adequate cardiac function13
  • Patients must agree to use methods of contraception as a agreed upon by the patient and study doctor

Exclusion Criteria:

  • Patient is pregnant or lactating
  • Radiation, chemotherapy, immunotherapy, any other systemic anticancer therapy, or participation in an investigational anti-cancer study ≤3 weeks prior to initiation of therapy.
  • Major surgery within 4 weeks before initiation of therapy
  • Unstable cardiovascular function
  • Active, ongoing or uncontrolled active infection within one week prior to first dose.
  • Malignancies other than disease under study within 2 years prior to Cycle 1, Day 1.
  • Known to be HIV seropositive
  • Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) RNA or hepatitis B virus (HBV) surface antigen (HBsAg)
  • Patients with active CNS malignancy.
  • Patients with any gastrointestinal dysfunctions that could interfere with the absorption of Selinexor or patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea.
  • Inability or unwillingness to take supportive medications such as anti-nausea and anti anorexia agents.
  • In the opinion of the Investigator, patients who are significantly below their ideal body weight
  • Serious psychiatric or medical conditions that could interfere with treatment
  • Concurrent therapy with approved or investigational anticancer therapeutic agents
  • Any condition that, in the opinion of the Investigator, would interfere with evaluation of the study regimen or interpretation of patient safety or study results

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03042819

Layout table for location information
Canada, Ontario
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
University Health Network, Toronto
Karyopharm Therapeutics Inc
Layout table for investigator information
Principal Investigator: Albiruni Razak, M.D. Princess Margaret Cancer Centre
Layout table for additonal information
Responsible Party: University Health Network, Toronto Identifier: NCT03042819    
Other Study ID Numbers: SAR-002
First Posted: February 3, 2017    Key Record Dates
Last Update Posted: September 25, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action